Countable Labs and Promega Announce Co-Marketing Agreement to Facilitate End-to End Biological Sample Preparation and Rare Variant Detection

Palo Alto, Calif. and Madison, Wis., USA. (July 6, 2026)

Countable Labs, the developer of Countable PCR, a breakthrough single-molecule PCR technology redefining how science measures biology, announced a co-marketing agreement with Promega, a leader in providing innovative solutions and technical support to the life sciences industry. The agreement brings together the capabilities of the Promega Maxwell® System for nucleic acid extraction and the Countable PCR instruments for complete, bias-free DNA and RNA extraction and quantification, combining products and expertise to offer customers a complete, practical and easy-to-use solution for DNA and RNA quantification.

The combined workflow leverages the Promega Maxwell® System, a reliable, fast, and simple automated benchtop nucleic acid extraction instrument which uses a paramagnetic, particle-based workflow to process up to 48 samples in parallel, delivering high-quality nucleic acids for a broad range of downstream applications. The nucleic acids are then analyzed with Countable PCR instruments, isolating single molecules across 30 million compartments for true single-molecule quantification and using the majority of extracted material as input — interrogating samples more completely to maximize detection of rare targets that other methods miss.

In a poster published by Countable Labs illustrating the utility of the workflow, total cfDNA was extracted from human blood plasma using a magnetic bead-based automated system (the Rapid ccfDNA Kit on the Maxwell® CSC system) to ensure consistent recovery from low-input material. When coupled with a pre-amplification step, a multiplexed KRAS assay using Countable PCR reached 0.08% MAF for G12C without compromising sensitivity for multiplexing. Results were reproducible across technical replicates and were achieved with minimal optimization.

Countable Labs is on a mission to unlock new possibilities in rare variant detection and quantification by
delivering the high sensitivity and robust scale that traditional PCR methods have never achieved.
“Countable PCR's ability to spatially isolate and detect single molecules across 30 million compartments
makes it an efficient solution for a range of translational research and diagnostics challenges from
monitoring minimal residual disease to pushing the boundaries of liquid biopsy,” said Anjali Pradhan,
Chief Business Officer at Countable Labs. “Partnering with Promega gives our customers a seamless,
end-to-end solution from sample to answer, empowering a new wave of precision medicine
innovation.”

“Promega and Countable Labs are aligned in our desire to provide flexible, best-in-class, solutions for life
sciences’ biggest technological challenges,” said Alok Sharma, Global Clinical Market Director at
Promega. “We designed our Maxwell® instruments and kits to provide the versatility our customers can
trust, enabling experiments that reliably and efficiently deliver high quality nucleic acids from a broad
range of sample input types and amounts, enabling many downstream applications.”

The companies are hosting a joint webinar on July 9, 2026, at 9 a.m. Pacific time which will cover the
complete liquid biopsy workflow from cfDNA extraction using the Promega Maxwell® System followed
by ultra-sensitive mutation detection using Countable PCR. For more information, or to register, visit
makeitcount.countablelabs.com/cfDNA-workflow-liquid-biopsy-webinar.

Countable Labs is transforming how biology is measured— bringing single-molecule precision to cell and gene therapy, oncology, molecular diagnostics, and other applications that demand the highest analytical performance. Countable PCR delivers at least 10 times the sensitivity of conventional PCR, with dynamic range and quantitative accuracy that existing digital PCR and next-generation sequencing approaches have not achieved — enabling detection and quantification of rare targets with a level of confidence that fundamentally changes what's measurable. Founded in 2019 and headquartered in Palo Alto, Calif., Countable Labs is privately held and backed by ARCH Venture Partners, F-Prime Capital, and Primer Ventures. Visit www.countablelabs.com to learn more or follow the company on LinkedIn or YouTube.

Countable Labs’ current products are for Research Use Only

Promega Corporation is a leading provider of innovative solutions and technical support for the life sciences industry. The company's portfolio comprises more than 4,000 products and supports a broad range of applications in the life sciences, including cell biology, DNA, RNA, and protein analysis, drug development, human identification, and molecular diagnostics. Since the company's founding in 1978, these tools and technologies have continuously evolved and are now used in more than 100 countries by scientists and technical professionals in laboratories for academic and government research, forensics, pharmaceuticals, clinical diagnostics, and agricultural and environmental testing. Promega is headquartered in Madison, Wisconsin (USA), and has a global presence with branch offices in 16 countries as well as more than 50 global distribution partners.

Promega GmbH, a subsidiary of Promega Corporation, has had a presence in Germany since 1997. The company headquarters — which include the European Instrument Service Center, the Customer Training Laboratory, and the European Logistics Center (EuroHub) — are located in Walldorf, Germany. With more than 170 employees, Promega GmbH is responsible for the sales and service of reagents and instruments in Germany, Austria, and Eastern Europe. For more information, please visit www.promega.com and follow us on YouTube, LinkedIn, Bluesky, Instagram, and the Promega Connections Blog.

Presse-Newsletter

Sie wollen über die Aktivitäten der Promega GmbH auf dem Laufenden bleiben? Hier können Sie sich für den Presse-Newsletter anmelden.